Advisory Alpha’s Biogen BIIB Stock Holding History

Advisory Alpha’s Portfolio BIIB Stock Details BIIB Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2020 Q4	–	Sell	-12	Closed	-$3K	–	165
2020 Q3	$3K	Buy	+12	New	+$3.35K	﹤0.01%	567
2020 Q2	–	Sell	-88	Closed	-$25.7K	–	145
2020 Q1	$25.7K	Sell	88 -46	-34%	-$14K	0.01%	284
2019 Q4	$39.4K	Buy	134 +102	+319%	+$28.3K	0.01%	307
2019 Q3	$7.11K	Buy	+32	New	+$7.45K	﹤0.01%	495
2019 Q2	–	Sell	-12	Closed	-$2.74K	–	169
2019 Q1	$2.74K	Buy	+12	New	+$3.78K	﹤0.01%	527

Other funds holding BIIB

Primecap Management Pasadena, California $169B AUM 114.72% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return

ClearBridge Investments New York $121B AUM 27.52% 1-Year Est. Return

Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return

JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Northern Trust Chicago, Illinois $860B AUM 41.15% 1-Year Est. Return

Advisory Alpha's BIIB Position: Q4 2020 in Review

Advisory Alpha sold out of Biogen (BIIB) in Q4 2020, closing a stake of 12 shares — an estimated $3K sold.

Advisory Alpha first reported a position in BIIB in Q1 2019 and held it in 5 quarters. The position peaked at $39.4K in Q4 2019. 1,062 funds tracked by Wall St. Rank hold BIIB as of Q4 2020.

Advisory Alpha reported no remaining Biogen position as of Q4 2020 after selling out during the quarter.
Advisory Alpha sold 12 Biogen shares in Q4 2020, an estimated $3K.
Advisory Alpha first reported a position in Biogen in Q1 2019 and held it in 5 quarters.
Advisory Alpha's Biogen position peaked at $39.4K in Q4 2019.
1,062 funds tracked by Wall St. Rank held Biogen as of Q4 2020.

Based on Advisory Alpha's 13F filing for Q4 2020, filed 16 Feb 2021.